key: cord-1030919-w8m5bvov
authors: Megna, M.; Napolitano, M.; Fabbrocini, G.
title: May IL-17 have a role in COVID-19 infection?
date: 2020-04-22
journal: Med Hypotheses
DOI: 10.1016/j.mehy.2020.109749
sha: 494cd44e9721024e89afa7377d397b3dfd51d188
doc_id: 1030919
cord_uid: w8m5bvov

nan

Dear Editor, SARS-Corona-Virus-2 related disease (COVID-19) which started in Wuhan, China on December 2019, is spreading rapidly throughout the world (1) . COVID-19 clinical spectrum is variable and may lead to respiratory failure, multiorgan and systemic manifestations (2) . COVID-19 patients showed lower leukocyte numbers, abnormal respiratory findings, and increased levels of plasma pro-inflammatory cytokines such as interleukin (IL)1-β, IL1RA, IL6, IL8, IL10 with Th1-Th17 cells appearing as the main source (3) . That is why recently tocilizumab, a monoclonal antibody blocking IL-6 action has been shown to be effective in COVID-19 subjects with cytokine storm risk (4) . Indeed, pro-inflammatory cytokine storms have been observed in critically COVID-19 patients which progress to multiple organ dysfunction and death (4, 5) . Therefore, cytokine storms early treatment and prevention is of crucial importance. In this context, the debate whether blocking other cytokines could reduce COVID-19 impact is growing (6) . Particularly, a cytokine that may be hypothesizing that blocking IL-17 could have the potential to improve COVID-19's aberrant immune response and acute respiratory distress syndrome-related mortality. 9, Indeed, a Chinese clinical trial evaluating an anti-IL17 drug approved for psoriasis (ixekizumab) is already running. 10 Despite the effect of blocking IL-17 on Th2 response should be deeper investigated since SARS-CoV-2 also seems to stimulate Th-2 cytokines production (IL-4 and IL-10) that suppress Th1/Th17 mediated inflammation (3), taken together all these data further underline the need of investigating on IL-17 blocking role in COVID19 which appears as a potential promising therapeutic target.

The coronavirus 2019-nCoV epidemic: Is hindsight 20/20? EClinicalMedicine

Evaluation and Treatment Coronavirus (COVID-19)

Clinical features of patients infected with 2019 novel coronavirus in

Tocilizumab treatment in COVID-19: a single center experience

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Should patients stop their biologic treatment during the COVID-19 pandemic

Interleukin-6 (IL-6) and IL-17 synergistically promote viral persistence by inhibiting cellular apoptosis and cytotoxic T cell function

Critical role of IL-17RA in immunopathology of influenza infection

Th17 serum cytokines in relation to laboratory-confirmed respiratory viral infection: a pilot study

The protective and pathogenic role of IL-17 in viral infection: friend or foe?

All authors declare to not have conflict of interest as well as funding sources to declare